Siga Technologies Inc. (NASDAQ:SIGA – Get Free Report) was the target of some unusual options trading on Wednesday. Stock traders purchased 1,200 call options on the stock. This is an increase of approximately 1,438% compared to the typical volume of 78 call options.
Analyst Upgrades and Downgrades
A number of research analysts have recently weighed in on SIGA shares. Wall Street Zen cut Siga Technologies from a “strong-buy” rating to a “hold” rating in a research report on Saturday, November 15th. Weiss Ratings cut shares of Siga Technologies from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Monday, January 26th. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat, Siga Technologies currently has a consensus rating of “Sell”.
Check Out Our Latest Stock Analysis on SIGA
Hedge Funds Weigh In On Siga Technologies
Siga Technologies Stock Down 3.3%
NASDAQ SIGA opened at $6.51 on Friday. The firm has a market cap of $466.18 million, a price-to-earnings ratio of 6.38 and a beta of 0.96. The business has a 50-day moving average price of $6.45 and a 200-day moving average price of $7.45. Siga Technologies has a twelve month low of $4.95 and a twelve month high of $9.62.
Siga Technologies (NASDAQ:SIGA – Get Free Report) last issued its earnings results on Thursday, November 6th. The company reported ($0.09) earnings per share (EPS) for the quarter. Siga Technologies had a net margin of 43.22% and a return on equity of 35.23%. The business had revenue of $2.62 million for the quarter. Research analysts expect that Siga Technologies will post 1.04 EPS for the current fiscal year.
About Siga Technologies
Siga Technologies, Inc (NASDAQ: SIGA) is a specialty pharmaceutical company focused on the development, manufacturing and commercialization of medical countermeasures for public health emergencies and biological threats. The company’s flagship product, TPOXX® (tecovirimat), is the first and only antiviral approved by the U.S. Food and Drug Administration for the treatment of smallpox. Siga has entered into procurement and development contracts with U.S. government agencies, including the Biomedical Advanced Research and Development Authority (BARDA) and the Department of Defense, to supply TPOXX® for the Strategic National Stockpile.
Founded in 2002, Siga has built a pipeline of therapies targeting high-consequence pathogens such as smallpox, plague and other potential biothreat agents.
Recommended Stories
- Five stocks we like better than Siga Technologies
- Free: The Crypto Summit That Could Change Your Life
- ~$1.5T SpaceX IPO: Pre-IPO Opportunity
- “Fed Proof” Your Bank Account with THESE 4 Simple Steps
- What a Former CIA Agent Knows About the Coming Collapse
- NEW LAW: Congress Approves Setup For Digital Dollar?
Receive News & Ratings for Siga Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Siga Technologies and related companies with MarketBeat.com's FREE daily email newsletter.
